Drug intelligence / Profile preview

AddKay

Development stage: Unknown
Lead developer: Steadfast Medishield
Modality: Small Molecules
Administration: Oral

Overview

AddKay is a solid oral dosage form of potassium chloride, developed and marketed by Steadfast Medishield (now Steadfast Limited) for renal care. It is an electrolyte replenisher formulated as a 750 mg prolonged-release tablet, providing 10 mEq of potassium. The prolonged-release mechanism is designed to minimize high, localized concentrations of potassium in the gastrointestinal tract, thereby reducing the risk of irritation or ulceration. Potassium is an essential ion involved in maintaining intracellular tonicity, nerve impulse transmission, and the contraction of cardiac, skeletal, and smooth muscles. AddKay is primarily indicated for the treatment and prevention of hypokalemia, particularly in patients with renal conditions or those on diuretic therapy.

Brand names: AddKay
Other names: potassium chloride

Beyond the preview

Go deeper on AddKay.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AddKay.

Explore the full profile